NLRP3 Inflammasome Inhibitors in Cardiovascular Diseases

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2021 Mar 6

PMID 33673188

Citations 26

Authors

Eleonora Mezzaroma

Antonio Abbate

Stefano Toldo

Affiliations

Soon will be listed here.

Abstract

Virtually all types of cardiovascular diseases are associated with pathological activation of the innate immune system. The NACHT, leucine-rich repeat (LRR), and pyrin domain (PYD)-containing protein 3 (NLRP3) inflammasome is a protein complex that functions as a platform for rapid induction of the inflammatory response to infection or sterile injury. NLRP3 is an intracellular sensor that is sensitive to danger signals, such as ischemia and extracellular or intracellular alarmins during tissue injury. The NLRP3 inflammasome is regulated by the presence of damage-associated molecular patterns and initiates or amplifies inflammatory response through the production of interleukin-1β (IL-1β) and/or IL-18. NLRP3 activation regulates cell survival through the activity of caspase-1 and gasdermin-D. The development of NLRP3 inflammasome inhibitors has opened the possibility to targeting the deleterious effects of NLRP3. Here, we examine the scientific evidence supporting a role for NLRP3 and the effects of inhibitors in cardiovascular diseases.

Citing Articles

Frontiers and Hotspot Evolution of NLRP3 Inflammasome in Myocardial Infarction Research: A Bibliometric Analysis From 2013 to 2024.

Wu J, Lan Q, Zhang D, Jian Y, Yu L, Hao R Cardiovasc Ther. 2025; 2025:5178894.

PMID: 40018377 PMC: 11865457. DOI: 10.1155/cdr/5178894.

Bromocriptine: does this drug of Parkinson's disease have a role in managing cardiovascular diseases?.

Kutikuppala L, Sharma S, Chavan M, Rangari G, Misra A, Innamuri S Ann Med Surg (Lond). 2024; 86(2):926-929.

PMID: 38333315 PMC: 10849299. DOI: 10.1097/MS9.0000000000001642.

High-Density Lipoproteins at the Interface between the NLRP3 Inflammasome and Myocardial Infarction.

Carmo H, Bonilha I, Barreto J, Tognolini M, Zanotti I, Sposito A Int J Mol Sci. 2024; 25(2).

PMID: 38279290 PMC: 10816227. DOI: 10.3390/ijms25021290.

[Isodopharicin C inhibits NLRP3 inflammasome activation and alleviates septic shock in mice].

Cao H, Zhang W, Li M, Yang Y, Li Y Nan Fang Yi Ke Da Xue Xue Bao. 2023; 43(9):1476-1484.

PMID: 37814861 PMC: 10563096. DOI: 10.12122/j.issn.1673-4254.2023.09.04.

Inhibitors of NLRP3 Inflammasome in Ischemic Heart Disease: Focus on Functional and Redox Aspects.

Pagliaro P, Penna C Antioxidants (Basel). 2023; 12(7).

PMID: 37507935 PMC: 10376505. DOI: 10.3390/antiox12071396.

References

Shao W, Yeretssian G, Doiron K, Hussain S, Saleh M . The caspase-1 digestome identifies the glycolysis pathway as a target during infection and septic shock. J Biol Chem. 2007; 282(50):36321-9. DOI: 10.1074/jbc.M708182200. View

Mauro A, Bonaventura A, Vecchie A, Mezzaroma E, Carbone S, Narayan P . The Role of NLRP3 Inflammasome in Pericarditis: Potential for Therapeutic Approaches. JACC Basic Transl Sci. 2021; 6(2):137-150. PMC: 7907621. DOI: 10.1016/j.jacbts.2020.11.016. View

Sandanger O, Ranheim T, Vinge L, Bliksoen M, Alfsnes K, Finsen A . The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury. Cardiovasc Res. 2013; 99(1):164-74. DOI: 10.1093/cvr/cvt091. View

Sanchez-Fernandez A, Skouras D, Dinarello C, Lopez-Vales R . OLT1177 (Dapansutrile), a Selective NLRP3 Inflammasome Inhibitor, Ameliorates Experimental Autoimmune Encephalomyelitis Pathogenesis. Front Immunol. 2019; 10:2578. PMC: 6839275. DOI: 10.3389/fimmu.2019.02578. View

Lima Jr H, Jacobson L, Goldberg M, Chandran K, Diaz-Griffero F, Lisanti M . Role of lysosome rupture in controlling Nlrp3 signaling and necrotic cell death. Cell Cycle. 2013; 12(12):1868-78. PMC: 3735701. DOI: 10.4161/cc.24903. View

Quader M, Mezzaroma E, Kenning K, Toldo S . Targeting the NLRP3 inflammasome to reduce warm ischemic injury in donation after circulatory death heart. Clin Transplant. 2020; 34(10):e14044. DOI: 10.1111/ctr.14044. View

Xiao H, Li H, Wang J, Zhang J, Shen J, An X . IL-18 cleavage triggers cardiac inflammation and fibrosis upon β-adrenergic insult. Eur Heart J. 2017; 39(1):60-69. DOI: 10.1093/eurheartj/ehx261. View

Abbate A, Van Tassell B, Seropian I, Toldo S, Robati R, Varma A . Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse. Eur J Heart Fail. 2010; 12(4):319-22. DOI: 10.1093/eurjhf/hfq017. View

Zhong Z, Liang S, Sanchez-Lopez E, He F, Shalapour S, Lin X . New mitochondrial DNA synthesis enables NLRP3 inflammasome activation. Nature. 2018; 560(7717):198-203. PMC: 6329306. DOI: 10.1038/s41586-018-0372-z. View

10.

Suetomi T, Willeford A, Brand C, Cho Y, Ross R, Miyamoto S . Inflammation and NLRP3 Inflammasome Activation Initiated in Response to Pressure Overload by Ca/Calmodulin-Dependent Protein Kinase II δ Signaling in Cardiomyocytes Are Essential for Adverse Cardiac Remodeling. Circulation. 2018; 138(22):2530-2544. PMC: 6309790. DOI: 10.1161/CIRCULATIONAHA.118.034621. View

11.

Toldo S, Mezzaroma E, Bressi E, Marchetti C, Carbone S, Sonnino C . Interleukin-1β blockade improves left ventricular systolic/diastolic function and restores contractility reserve in severe ischemic cardiomyopathy in the mouse. J Cardiovasc Pharmacol. 2014; 64(1):1-6. DOI: 10.1097/FJC.0000000000000106. View

12.

Salloum F, Chau V, Varma A, Hoke N, Toldo S, Biondi-Zoccai G . Anakinra in experimental acute myocardial infarction--does dosage or duration of treatment matter?. Cardiovasc Drugs Ther. 2008; 23(2):129-35. DOI: 10.1007/s10557-008-6154-3. View

13.

Umemura K, Kikuchi S, Suzuki Y, Nakashima M . Inhibitory effect of tranilast on hypertrophic collagen production in the spontaneously hypertensive rat heart. Jpn J Pharmacol. 1998; 78(2):161-7. DOI: 10.1254/jjp.78.161. View

14.

Di Virgilio F, Sarti A, Coutinho-Silva R . Purinergic signaling, DAMPs, and inflammation. Am J Physiol Cell Physiol. 2020; 318(5):C832-C835. DOI: 10.1152/ajpcell.00053.2020. View

15.

Tozaki-Saitoh H, Sasaki I, Yamashita T, Hosoi M, Kato T, Tsuda M . Involvement of exchange protein directly activated by cAMP and tumor progression locus 2 in IL-1β production in microglial cells following activation of β-adrenergic receptors. J Pharmacol Sci. 2020; 143(3):133-140. DOI: 10.1016/j.jphs.2020.03.004. View

16.

Audia J, Yang X, Crockett E, Housley N, Haq E, ODonnell K . Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function. Basic Res Cardiol. 2018; 113(5):32. PMC: 6396295. DOI: 10.1007/s00395-018-0692-z. View

17.

Pazar B, Ea H, Narayan S, Kolly L, Bagnoud N, Chobaz V . Basic calcium phosphate crystals induce monocyte/macrophage IL-1β secretion through the NLRP3 inflammasome in vitro. J Immunol. 2011; 186(4):2495-502. DOI: 10.4049/jimmunol.1001284. View

18.

Leung Y, Hui L, Kraus V . Colchicine--Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015; 45(3):341-50. PMC: 4656054. DOI: 10.1016/j.semarthrit.2015.06.013. View

19.

Hausmann A, Bock D, Geiser P, Berthold D, Fattinger S, Furter M . Intestinal epithelial NAIP/NLRC4 restricts systemic dissemination of the adapted pathogen Salmonella Typhimurium due to site-specific bacterial PAMP expression. Mucosal Immunol. 2020; 13(3):530-544. PMC: 7181392. DOI: 10.1038/s41385-019-0247-0. View

20.

Van Tassell B, Toldo S, Mezzaroma E, Abbate A . Targeting interleukin-1 in heart disease. Circulation. 2013; 128(17):1910-23. PMC: 3938092. DOI: 10.1161/CIRCULATIONAHA.113.003199. View